(Q43737489)

English

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 November 2017

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study (English)

1 reference

Europe PubMed Central

26 November 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Jelić S

1

1 reference

Europe PubMed Central

26 November 2017

Mitrović L

2

1 reference

Europe PubMed Central

26 November 2017

Radosavljević D

3

1 reference

Europe PubMed Central

26 November 2017

Elezar E

4

1 reference

Europe PubMed Central

26 November 2017

Babović N

5

1 reference

Europe PubMed Central

26 November 2017

Kovcin V

6

1 reference

Europe PubMed Central

26 November 2017

Tomasević Z

7

1 reference

Europe PubMed Central

26 November 2017

Kovacević S

8

1 reference

Europe PubMed Central

26 November 2017

Gavrilović D

9

1 reference

Europe PubMed Central

26 November 2017

Radulović S

10

1 reference

Europe PubMed Central

26 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2001

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

34

1 reference

Europe PubMed Central

26 November 2017

1

1 reference

Europe PubMed Central

26 November 2017

1-13

1 reference

Europe PubMed Central

26 November 2017

Combination chemotherapy with mitomycin, vindesine, and cisplatin for non-small cell lung cancer. Association of antitumor activity with initial tumor burden and treatment center

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin versus cisplatin in solid tumors: an analysis of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin: current status and future prospects

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Carboplatin and cisplatin: are they equivalent in efficacy in "optimal residual" advanced ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of paclitaxel and carboplatin for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic analysis of carboplatin versus cisplatin in lung and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0169-5002%2801%2900239-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0169-5002(01)00239-2

1 reference

Europe PubMed Central

26 November 2017

1 reference

Europe PubMed Central

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43737489&oldid=2102936276"